Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL1CC Injection in Relapsed/Refractory Acute Myeloid Leukemia
NCT07841002Phase 1Not yet recruiting
- Sponsor
- Liping Dou
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SL1CC in acute myeloid leukemia (AML), sponsored by Liping Dou. Primary endpoints: Incidence and Severity of Adverse Events and Serious Adverse Events at 24 months and Incidence of Dose-Limiting Toxicities at 28 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SL1CC
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07841002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07841002.